FDA Says Diabetes Drugs Onglyza, Nesina May Increase Heart Failure Risk

(April 6, 2016, 11:20 AM EDT) -- SILVER SPRING, Md. — The diabetes drugs Onglyza and Nesina may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, the Food and Drug Administration said April 5.

The active pharmaceutical ingredient in the drugs are saxagliptin and alogliptin, the FDA said. Saxagliptin is in Onglyza and Kombiglyze, the second of which is a combination drug with metformin, another diabetes drug.

Alogliptin is in Nesina, Kazano (a combination with metformin) and Oseni (a combination with pioglitazone).

New Warnings Added...
To view the full article, register now.